Neogenomics Inc's Corporate Customers have recorded an advance in their cost of revenue by 8.59 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -6.12 %. During the corresponding time, Neogenomics Inc recorded a revenue increase by 11.13 % year on year, sequentially revenue fell by -2.86 %. While revenue at the Neogenomics Inc 's corporate clients recorded rose by 5.99 % year on year, sequentially revenue fell by -4.9 %.
Neogenomics Inc's Customers have recorded an advance in their cost of revenue by 8.59 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -6.12 %, for the same period Neogenomics Inc recorded revenue increase by 11.13 % year on year, sequentially revenue fell by -2.86 %.
Neogenomics Inc's Comment on Sales, Marketing and Customers
The company provides oncology testing services to clinical and pharmaceutical clients, including diagnostic testing, therapy selection, and molecular residual disease testing. Its customers include physicians, healthcare providers, clinical trial organizers, commercial laboratories, and academically affiliated laboratories serving university hospitals and associated physicians. The company's market segments encompass diagnostic testing such as pap smears, skin biopsies, and tissue biopsies; therapy selection through gene and protein analysis; and molecular residual disease testing to monitor cancer treatment effectiveness. It specializes in precision oncology, offering predictive testing to support personalized medicine treatments including Herceptin®, Keytruda®, PIQRAY®, and Opdivo®.
Neogenomics Inc’s Comment on Sales, Marketing and Customers
The company provides oncology testing services to clinical and pharmaceutical clients, including diagnostic testing, therapy selection, and molecular residual disease testing. Its customers include physicians, healthcare providers, clinical trial organizers, commercial laboratories, and academically affiliated laboratories serving university hospitals and associated physicians. The company's market segments encompass diagnostic testing such as pap smears, skin biopsies, and tissue biopsies; therapy selection through gene and protein analysis; and molecular residual disease testing to monitor cancer treatment effectiveness. It specializes in precision oncology, offering predictive testing to support personalized medicine treatments including Herceptin®, Keytruda®, PIQRAY®, and Opdivo®.
Sources:
Neogenomics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Neogenomics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Neogenomics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
145.02 %
3.99 %